Spray Dried ID93+GLA-SE

By WGNV | September 15, 2023

AAHI’s tuberculosis vaccine candidate includes a recombinant fusion subunit protein antigen, ID93, formulated with GLA-SE, a squalene emulsion containing the synthetic Toll-like receptor 4 agonist glucopyranosyl lipid A (GLA). The vaccine candidate was developed on AAHI’s formulation (adjuvant and delivery vehicle) vaccine platform.

Read More

TB/FLU-05E

By JWoolley | July 17, 2023

TB/FLU-05E is a mucosal TB vaccine candidate based on recombinant attenuated influenza vector (Flu/THSP) co-expressing truncated NS1 protein NS1(1–124) and a full-length TB10.4 and HspX proteins of M.tb within an NS1 protein open reading frame. Vaccine formulation: Liquid nasal spray.

Read More

BCG (Travel vaccine)*

By JWoolley | September 12, 2022

The purpose of this trial (TIPI Trial), is to find out if a single dose of pre-travel vaccination with BCG can lessen tuberculosis (TB) infection by producing an immune response when given to adults traveling to countries with a high burden of TB. BCG (Tokyo 172), supplied by Japan BCG Lab, will be compared with…

Read More